GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (DUB:MLC) » Definitions » Total Liabilities

Malin (DUB:MLC) Total Liabilities : €10.20 Mil (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Malin Total Liabilities?

Malin's Total Liabilities for the quarter that ended in Jun. 2024 was €10.20 Mil.

Malin's quarterly Total Liabilities increased from Jun. 2023 (€5.60 Mil) to Dec. 2023 (€7.10 Mil) and increased from Dec. 2023 (€7.10 Mil) to Jun. 2024 (€10.20 Mil).

Malin's annual Total Liabilities declined from Dec. 2021 (€9.30 Mil) to Dec. 2022 (€4.80 Mil) but then increased from Dec. 2022 (€4.80 Mil) to Dec. 2023 (€7.10 Mil).


Malin Total Liabilities Historical Data

The historical data trend for Malin's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Malin Total Liabilities Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 92.70 80.50 9.30 4.80 7.10

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.50 4.80 5.60 7.10 10.20

Malin Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Malin's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1+(0+6.1
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=7.10

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=116.6-109.5
=7.10

Malin's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.5+(0+9.7
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=10.20

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=128.4-118.2
=10.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Malin Total Liabilities Related Terms

Thank you for viewing the detailed overview of Malin's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Malin Business Description

Traded in Other Exchanges
Address
50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a global life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. Its subsidiary income is derived from the sale of pharmaceutical products.

Malin Headlines

No Headlines